A Phase 1/2 interventional study of NKTR-262 and bempegaldesleukin in Melanoma, Merkel Cell Carcinoma and Triple Negative Breast Cancer, sponsored by Nektar Therapeutics. Terminated at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-08.
Sponsored by Nektar Therapeutics · Phase 1/2, Interventional, and Treatment
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable toxicity, death, or disease progression per RECIST 1.1. Based on Phase 1 results of the study, the decision was made not to start the Phase 2 part of the study and the study was terminated.
Cancer treatments that couple pharmacological activation of tumor antigen presentation with activation and expansion of CD8+ T and natural killer (NK) cells in the tumor environment have the potential to induce an effective anti-tumor immune response in patients. NKTR-262 is a small molecule agonist of toll-like receptors (TLRs) 7/8 designed to be retained in the tumor micro-environment in order to activate antigen-presenting cells (APC), such as dendritic cells, to create new antigen-specific cytotoxic T cells. As a CD122-biased agonist, bempegaldesleukin monotherapy increases newly proliferative CD8+ T cells in tumors. NKTR-262 plus bempegaldesleukin is expected to increase expansion of antigen-specific CD8+ T cells. In preclinical studies, a single IT injection of NKTR-262 plus IV bempegaldesleukin resulted in complete abscopal effects in tumor models. Preliminary clinical data show bempegaldesleukin plus nivolumab enhances immune-stimulatory responses. The REVEAL trial will assess safety and anti-tumor activity of NKTR-262 with bempegaldesleukin +/- nivolumab for the treatment of selected cancers.
3,370 studies on the registry are indexed under Melanoma; 578 are open to participants now.
This study's enrollment of 64 is above the median of 40 across 2,649 interventional studies indexed under Melanoma.
Browse Melanoma studies →Nektar Therapeutics is the lead sponsor of 39 studies on the registry; 2 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 13 (59%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
History of unstable or deteriorating cardiac disease within the previous 6 months prior to screening including but not limited to the following:
Additional general and tumor specific inclusion and exclusion criteria will apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumour measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumour visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumours on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumour 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumour sample. Some scores count stained tumour cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1: NKTR-262 in escalating doses, combined with bempegaldesleukin. The goal of this dose escalation part of the study is to establish a recommended Phase 1b dose for NKTR-262 + bempegaldesleukin with nivolumab, followed by a dose-confirmation cohort.
Drug: NKTR-262 · Drug: bempegaldesleukin · Drug: nivolumab
During Phase 1 Doublet: Patients receive escalating doses of NKTR-262 IT (starting dose 0.03 mg) in 3-week treatment cycles. During Phase 1 Doublet (Cohort A), Phase 2 Doublet: Patients were to receive the RP2D of NKTR-262. During Phase 1 Triplet (Cohort B), and Phase 2 Triplet: Patients receive the RP2D of NKTR-262.
During Phase 1 Doublet (Cohort A), and proposed Phase 2 Doublet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles. During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive 0.006 mg/kg bempegaldesleukin administered in 3-week treatment cycles.
Also known as: NKTR-214
During Phase 1 Triplet (Cohort B), and proposed Phase 2 Triplet: Patients receive a nivolumab flat dose of 360 mg administered in 3-week treatment cycles.
Also known as: Opdivo®
Number of Participants Experiencing Dose-Limiting Toxicities (DLTS)
DLTs were assessed in Cohort 1 through Cohort 9, which had dose levels of NKTR-262 as 0.03mg, 0.06mg, 0.06mg, 0.12mg, 0.24mg, 0.48mg, 0.96mg, 1.92mg, and 3.84mg in combination with bempegaldesleukin (bempeg). There was only 1 DLT that occurred in one of the Cohort 9 patients. Therefore, the maximum tolerated dose (MTD) of NKTR 262 was not reached.
Time frame: The DLT window is 21 days following NKTR-262 single agent administration (Cycle 1) and an additional 9 days when combined with bempeg for staggered dosing administration (Cohorts 1 and 2), or 7 days for the same day administration (Cohort 3 and higher).
Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D)
Objective Response Rate (ORR) per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D). ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by Blinded Independent Central Review (BICR).
Time frame: From Cycle 1 Day 1 to 100 days after the last dose of study drug or the date for new anti-cancer therapy, whichever is earlier.
| Milestone | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 3 | 8 | 14 | 14 |
| Completed | 3 | 2 | 3 | 1 | 4 | 4 | 1 | 3 | 8 | 12 | 11 |
| Not completed | 0 | 1 | 1 | 2 | 0 | 0 | 3 | 0 | 0 | 2 | 3 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DLTs were assessed in Cohort 1 through Cohort 9, which had dose levels of NKTR-262 as 0.03mg, 0.06mg, 0.06mg, 0.12mg, 0.24mg, 0.48mg, 0.96mg, 1.92mg, and 3.84mg in combination with bempegaldesleukin (bempeg). There was only 1 DLT that occurred in one of the Cohort 9 patients. Therefore, the maximum tolerated dose (MTD) of NKTR 262 was not reached.
| Participants | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Experiencing Dose-Limiting Toxicities (DLTS) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
Objective Response Rate (ORR) per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D). ORR is defined as the percentage of subjects with evidence of a confirmed complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 and as assessed by Blinded Independent Central Review (BICR).
| percentage of participants | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab |
|---|---|---|
| Objective Response Rate (ORR) Per RECIST 1.1 in Cohort A and Cohort B at Recommended Phase 2 Dose (RP2D) | 0 (0.0 to 23.2) | 14.3 (1.8 to 42.8) |
Collected over 4 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | 3/4 (75%) | 1/4 (25%) | 4/4 (100%) |
| Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | 1/4 (25%) | 1/4 (25%) | 4/4 (100%) |
| Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | 2/3 (66.7%) | 3/3 (100%) | 3/3 (100%) |
| Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 5/8 (62.5%) | 3/8 (37.5%) | 8/8 (100%) |
| Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | 9/14 (64.3%) | 2/14 (14.3%) | 14/14 (100%) |
| Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | 5/14 (35.7%) | 5/14 (35.7%) | 14/14 (100%) |
| Event | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SyncopeNervous system disorders | 0/3 | 0/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 1/3 | 0/8 | 1/14 | 0/14 |
| Cerebral infarctionNervous system disorders | 0/3 | 0/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 1/3 | 0/8 | 0/14 | 0/14 |
| Haemorrhage intracranialNervous system disorders | 1/3 | 0/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/8 | 0/14 | 0/14 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 0/3 | 1/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/8 | 0/14 | 0/14 |
| AnaemiaBlood and lymphatic system disorders | 1/3 | 0/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/8 | 0/14 | 1/14 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/3 | 0/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 1/3 | 0/8 | 0/14 | 0/14 |
| Cytokine release syndromeImmune system disorders | 0/3 | 0/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 1/3 | 0/8 | 0/14 | 0/14 |
| Amylase increasedInvestigations | 0/3 | 0/3 | 0/4 | 1/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/8 | 0/14 | 0/14 |
| Lipase increasedInvestigations | 0/3 | 0/3 | 0/4 | 1/3 | 0/4 | 0/4 | 0/4 | 0/3 | 0/8 | 0/14 | 0/14 |
| NephrolithiasisRenal and urinary disorders | 0/3 | 0/3 | 0/4 | 0/3 | 0/4 | 0/4 | 0/4 | 1/3 | 0/8 | 0/14 | 0/14 |
| Event | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 2/3 | 3/3 | 2/4 | 1/3 | 3/4 | 2/4 | 3/4 | 1/3 | 4/8 | 8/14 | 6/14 |
| PyrexiaGeneral disorders | 0/3 | 2/3 | 2/4 | 1/3 | 2/4 | 2/4 | 2/4 | 3/3 | 2/8 | 2/14 | 9/14 |
| NauseaGastrointestinal disorders | 0/3 | 3/3 | 2/4 | 1/3 | 2/4 | 2/4 | 2/4 | 3/3 | 5/8 | 8/14 | 8/14 |
| ChillsGeneral disorders | 0/3 | 1/3 | 1/4 | 1/3 | 3/4 | 1/4 | 0/4 | 0/3 | 1/8 | 1/14 | 5/14 |
| Oedema peripheralGeneral disorders | 0/3 | 1/3 | 0/4 | 0/3 | 2/4 | 3/4 | 0/4 | 0/3 | 0/8 | 1/14 | 2/14 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/3 | 1/3 | 1/4 | 0/3 | 0/4 | 3/4 | 1/4 | 0/3 | 3/8 | 4/14 | 5/14 |
| DizzinessNervous system disorders | 0/3 | 0/3 | 0/4 | 0/3 | 0/4 | 3/4 | 0/4 | 1/3 | 2/8 | 2/14 | 1/14 |
| Influenza like illnessGeneral disorders | 2/3 | 0/3 | 2/4 | 1/3 | 2/4 | 2/4 | 0/4 | 1/3 | 5/8 | 8/14 | 6/14 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 0/3 | 1/4 | 1/3 | 2/4 | 2/4 | 1/4 | 1/3 | 3/8 | 7/14 | 6/14 |
| VomitingGastrointestinal disorders | 0/3 | 2/3 | 0/4 | 2/3 | 1/4 | 1/4 | 0/4 | 1/3 | 5/8 | 4/14 | 5/14 |
| Age, Categorical(Participants) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 3 | 2 | 2 | 2 | 1 | 3 | 3 | 8 | 10 | 8 | 43 |
| >=65 years | 2 | 0 | 2 | 1 | 2 | 3 | 1 | 0 | 0 | 4 | 6 | 21 |
| Age, Continuous(years) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.0 (63 to 69) | 53.0 (39 to 64) | 51.5 (32 to 71) | 56.3 (39 to 73) | 57.0 (41 to 74) | 68.0 (58 to 79) | 55.3 (40 to 72) | 59.0 (58 to 61) | 49.0 (35 to 63) | 57.7 (30 to 81) | 60.3 (28 to 79) | 57.4 (28 to 81) |
| Sex: Female, Male(Participants) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 1 | 1 | 2 | 1 | 2 | 2 | 1 | 0 | 5 | 4 | 7 | 26 |
| Male | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 10 | 7 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 |
| Not Hispanic or Latino | 3 | 3 | 4 | 2 | 3 | 4 | 4 | 3 | 8 | 13 | 13 | 60 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| White | 3 | 3 | 4 | 3 | 3 | 4 | 3 | 3 | 8 | 11 | 14 | 59 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 3 | 3 | 4 | 3 | 4 | 4 | 4 | 3 | 8 | 14 | 14 | 64 |
| ECOG Performance Status(Participants) | Cohort 1 NKTR-262 (0.03 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 2 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered Staggered) | Cohort 3 NKTR-262 (0.06 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 4 NKTR-262 (0.12 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 5 NKTR-262 (0.24 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 6 NKTR-262 (0.48 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 7 NKTR-262 (0.96 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 8 NKTR-262 (1.92 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort 9 NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort A NKTR-262 (3.84 mg) + Bempegaldesleukin (Administered the Same Day) | Cohort B NKTR-262 (3.84 mg) + Bempegaldesleukin + Nivolumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ECOG 0 | 2 | 1 | 2 | 1 | 2 | 2 | 3 | 3 | 6 | 7 | 5 | 34 |
| ECOG 1 | 1 | 2 | 2 | 2 | 2 | 2 | 1 | 0 | 2 | 7 | 9 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.